tiprankstipranks
Trending News
More News >
Zylox-Tonbridge Medical Technology Co., Ltd. Class H (HK:2190)
:2190
Advertisement

Zylox-Tonbridge Medical Technology Co., Ltd. Class H (2190) AI Stock Analysis

Compare
1 Followers

Top Page

HK:2190

Zylox-Tonbridge Medical Technology Co., Ltd. Class H

(Frankfurt:2190)

Rating:59Neutral
Price Target:
HK$26.00
▲(13.04% Upside)
Zylox-Tonbridge Medical Technology's strong revenue growth and improving profitability are overshadowed by significant cash flow challenges. While technical indicators show positive market momentum, overbought conditions present risks. The stock appears overvalued based on its high P/E ratio, and the low dividend yield offers limited income potential.
Positive Factors
Financial Performance
Adjusted net income surged by 68.1% year over year to Rmb131mn, reaching an adjusted net margin of 27.3%.
Market Entry
VBP guidelines are becoming more lenient, allowing new entrants to participate at the average bidding price from the last round, which should benefit quality new domestic entrants like Zylox.
Stock Outlook
The price target is increased, indicating a positive outlook for the stock's future value.
Negative Factors
Operating Expenses
Notable declines in the operating expenses ratio contribute to a better financial outlook.

Zylox-Tonbridge Medical Technology Co., Ltd. Class H (2190) vs. iShares MSCI Hong Kong ETF (EWH)

Zylox-Tonbridge Medical Technology Co., Ltd. Class H Business Overview & Revenue Model

Company DescriptionZylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices China and internationally. It primarily offers ThromBite Clot Retriever Device, which is intended to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke; Balloon Guiding Catheter; Cylone Aspiration Catheter; ZENFLEX Pro Peripheral Drug-eluting Stent System for complex lesions and restenotic symptomatic lesions; ZENFlex Peripheral Stent System to deliver a self-expanding stent to the iliac artery, superficial femoral arteries, and/or proximal popliteal arteries through a 6F delivery system; and drug-coated percutaneous transluminal angioplasty (PTA) Balloon Catheters that are indicated for PTA of stenosis or occlusion lesions in iliac, femoral, or popliteal arteries. The company also provides Ton-Bridge extra soft coils for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities, such as arteriovenous malformations and arteriovenous fistulae; microcatheter for coiling; distal access catheter; glycine micro catheter for professional physician to selectively inject or input control medium and/or embolic materials, and/or appropriate devices; Intracranial PTA balloon catheter; vascular snare; and snare retrieval kit for IVC filter. Zylox-Tonbridge Medical Technology Co., Ltd. was incorporated in 2012 and is headquartered in Zhejiang, the People's Republic of China.
How the Company Makes MoneyZylox-Tonbridge Medical Technology Co., Ltd. generates revenue primarily through the sale of its medical devices to hospitals, clinics, and healthcare providers. The company's key revenue streams include the direct sale of its neurovascular and peripheral vascular intervention products. Additionally, the company may engage in partnerships or collaborations with healthcare institutions and distributors to expand its market reach. Factors contributing to its earnings include ongoing innovation in product development, a strong distribution network, and its ability to meet regulatory standards for medical devices in various regions.

Zylox-Tonbridge Medical Technology Co., Ltd. Class H Financial Statement Overview

Summary
Zylox-Tonbridge Medical Technology shows impressive revenue growth and improved profitability with a strong balance sheet. However, cash flow challenges persist, indicating a need for more stable cash generation from operations.
Income Statement
78
Positive
Zylox-Tonbridge Medical Technology shows significant revenue growth, with revenue increasing from HKD 5 million in 2019 to HKD 782 million in 2024. The gross profit margin has been consistently high, reaching 71.5% in 2024. Profitability has improved, with the net profit margin turning positive at 12.8% in 2024, up from negative margins in previous years. However, there were periods of EBIT and EBITDA losses, indicating operational challenges before 2024.
Balance Sheet
85
Very Positive
The company maintains a strong equity position, with a high equity ratio of 89.8% in 2024, reflecting financial stability. The debt-to-equity ratio has remained low, minimizing financial risk. High cash reserves and negative net debt emphasize liquidity strength. However, consistent growth in total liabilities over the years warrants monitoring.
Cash Flow
40
Negative
Zylox-Tonbridge has faced challenges with cash flow generation, as evidenced by fluctuating and often negative free cash flows. Operating cash flow turned negative in 2024, impacting cash flow sustainability. The reliance on financing activities in earlier years highlights the need for improved cash flow from operations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue782.48M527.75M334.09M177.91M27.63M
Gross Profit559.89M384.99M252.67M131.88M16.29M
EBITDA65.30M-41.60M-86.56M-199.94M-90.16M
Net Income100.26M-78.73M-120.41M-186.05M-99.48M
Balance Sheet
Total Assets3.45B3.38B3.25B3.25B503.97M
Cash, Cash Equivalents and Short-Term Investments1.28B1.51B1.86B2.93B317.26M
Total Debt90.91M55.88M14.00M9.40M34.22M
Total Liabilities351.56M328.32M159.54M103.61M79.28M
Stockholders Equity3.10B3.05B3.09B3.14B424.69M
Cash Flow
Free Cash Flow-17.26M-92.48M-236.60M-205.80M-127.47M
Operating Cash Flow174.08M98.44M-91.32M-116.21M-82.33M
Investing Cash Flow-801.36M-206.24M-95.05M-1.33B-249.18M
Financing Cash Flow-41.98M-11.46M-30.26M2.81B345.54M

Zylox-Tonbridge Medical Technology Co., Ltd. Class H Technical Analysis

Technical Analysis Sentiment
Positive
Last Price23.00
Price Trends
50DMA
21.85
Positive
100DMA
20.21
Positive
200DMA
16.20
Positive
Market Momentum
MACD
0.32
Positive
RSI
52.41
Neutral
STOCH
32.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2190, the sentiment is Positive. The current price of 23 is above the 20-day moving average (MA) of 22.91, above the 50-day MA of 21.85, and above the 200-day MA of 16.20, indicating a bullish trend. The MACD of 0.32 indicates Positive momentum. The RSI at 52.41 is Neutral, neither overbought nor oversold. The STOCH value of 32.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2190.

Zylox-Tonbridge Medical Technology Co., Ltd. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
HK$7.59B44.834.99%0.47%35.01%483.73%
51
Neutral
$7.86B-0.26-41.41%2.22%22.87%-2.01%
€543.41M-11.20%
73
Outperform
HK$8.42B109.551.98%3.42%-70.82%
66
Neutral
HK$7.64B34.5311.79%1.45%-5.18%-9.69%
64
Neutral
HK$8.46B41.424.39%0.98%-32.05%-54.47%
62
Neutral
HK$6.28B19.6211.24%1.29%25.18%55.79%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
23.00
12.06
110.30%
DE:4WO
Peijia Medical Ltd.
0.80
0.34
73.91%
HK:1302
LifeTech Scientific Corporation
1.95
0.55
39.29%
HK:1789
AK Medical Holdings Ltd.
5.60
1.49
36.25%
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
14.87
8.19
122.60%
HK:2172
MicroPort NeuroTech Limited
13.06
5.15
65.11%

Zylox-Tonbridge Medical Technology Co., Ltd. Class H Corporate Events

Zylox-Tonbridge Projects Strong Financial Growth in H1 2025
Jul 23, 2025

Zylox-Tonbridge Medical Technology Co., Ltd. has announced a significant increase in its financial performance for the first half of 2025, with revenue expected to exceed RMB480 million, a 31.1% increase from the previous year. This growth is attributed to strong sales of key products and an effective sales strategy. Net profit is also anticipated to rise by 66.9% to over RMB115 million, driven by increased revenue, stable gross profit margins, and enhanced operational efficiency.

The most recent analyst rating on (HK:2190) stock is a Buy with a HK$18.60 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

Zylox-Tonbridge Schedules Board Meeting to Review Interim Results
Jul 22, 2025

Zylox-Tonbridge Medical Technology Co., Ltd. has announced an upcoming board meeting scheduled for August 19, 2025. The meeting will focus on approving and publishing the interim results for the first half of the year, which could have implications for the company’s financial performance and market positioning.

The most recent analyst rating on (HK:2190) stock is a Buy with a HK$18.60 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

Zylox-Tonbridge Grants 250,000 Awards to Boost Long-term Growth
Jul 15, 2025

Zylox-Tonbridge Medical Technology Co., Ltd. has granted 250,000 awards under its Share Award Scheme to a service provider involved in consultancy services related to the company’s product development. This grant aims to recognize and motivate the service provider, aligning their interests with the company’s long-term growth objectives. The awards are subject to performance targets and a clawback mechanism, ensuring alignment with the company’s strategic goals.

The most recent analyst rating on (HK:2190) stock is a Buy with a HK$18.60 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

Zylox-Tonbridge Medical Technology Co., Ltd. Holds Successful 2024 AGM
May 30, 2025

Zylox-Tonbridge Medical Technology Co., Ltd. successfully held its 2024 Annual General Meeting (AGM) on May 30, 2025, where all proposed resolutions were approved unanimously. The meeting was conducted in compliance with relevant laws and regulations, with a significant portion of the company’s shares represented in the voting process, indicating strong shareholder support and engagement.

The most recent analyst rating on (HK:2190) stock is a Buy with a HK$18.60 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

Zylox-Tonbridge Updates Final Dividend Details for 2024
May 30, 2025

Zylox-Tonbridge Medical Technology Co., Ltd. has announced an update regarding its final dividend for the year ended December 31, 2024. The dividend is set at RMB 0.1 per share, with a payment in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.089909. The ex-dividend date is June 4, 2025, and the payment date is June 27, 2025. The company will withhold a 10% tax for non-resident enterprise shareholders and a 20% tax for domestic individual shareholders, reflecting its compliance with tax regulations.

The most recent analyst rating on (HK:2190) stock is a Buy with a HK$18.60 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 29, 2025